PYC Thera. (PYC) is held by 5 ASX ETFs. Over the last year it rose 123.7%: on $10,000, +$12368. We explain 9 big moves in that time.
About PYC
- SectorHealth Care
- IndustryPharmaceuticals, Biotechnology & Life Sciences
- Size$2.5b
- Held by5 ETFs
- Big moves9 in 1Y
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- +7.9%18 Sep 2026· Contract
PYC Therapeutics rose on momentum from a clinical milestone — dosing the first patient in its PKD open-label extension study — amplified by a run of bullish media coverage highlighting strong recent share price performance and pipeline progress.
- +6.1%2 Sep 2026· Earnings Beat
PYC Therapeutics shares rose after its full-year results showed a narrowed net loss, which was received positively by the market in the days following the annual report release.
- −5.9%21 Aug 2026· Sector Flow
PYC Therapeutics fell alongside a broad sell-off in the Australian healthcare sector, with no company-specific news to explain the move.
- +9.6%4 Aug 2026· Operational
PYC Therapeutics shares rose 9.62% on August 4, 2026, as the company's kidney trial advanced into multiple dosing, attracting investor attention.
- +6.2%3 Aug 2026· Sector Flow
PYC Therapeutics rose in line with a broad healthcare sector rally on the ASX, which was up over 2.3% on the same day.
- +7.9%13 May 2026· Unknown
No specific news was found; the price move is unexplained with available data.
- +5.5%13 May 2026· Unknown
No specific news articles were found to explain the price movement, so the cause remains unidentified.
- +5.9%1 Apr 2026· Sector Flow
Biotech sector selloff in March likely caused a modest rebound for PYC Therapeutics, with no stock-specific news.
- −6.0%27 Mar 2026· Unknown
No specific company news explains the move; likely market-wide sector or macro-driven selling pressure.
Held by 5 ETFs
Of every $10,000 in each fund, how much is in PYC today.
Why did PYC rise 5.9% on 1 Apr 2026?
PYC Thera.
Biotech sector selloff in March likely caused a modest rebound for PYC Therapeutics, with no stock-specific news.
The only relevant news is a Stockhead article reviewing biotech winners/losers in March, suggesting broad sector volatility. No direct PYC-specific news is present, and the price move is modest with volume slightly above average, indicating a sector-driven bounce rather than company-specific catalyst.
General information only, not personal advice — prepared without regard to your objectives, financial situation or needs. Past performance is not indicative of future performance.
Evidence
News coverage
What it did to the 5 ETFs holding PYC
On $10,000 in each fund, at the weight it holds today